Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease

NCT05804383 is registered in ClinicalTrials.gov with Allyx Therapeutics as lead sponsor.

NCT NCT05804383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05804383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease
Lead sponsor
Allyx Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2023
Completion date
October 15, 2025
Enrollment
51 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease